Holen Sie sich die Stockscreener-App
95.76
0.23%
-0.22
Schlusskurs vom Vortag:
$95.98
Offen:
$95.9
24-Stunden-Volumen:
1.69M
Relative Volume:
0.75
Marktkapitalisierung:
$7.26B
Einnahmen:
$35.93M
Nettoeinkommen (Verlust:
$-244.56M
KGV:
-24.24
EPS:
-3.95
Netto-Cashflow:
$-157.31M
1W Leistung:
-0.20%
1M Leistung:
+1.23%
6M Leistung:
+121.62%
1J Leistung:
+115.89%
1-Tages-Spanne:
$95.69
$95.96
1-Wochen-Bereich:
$95.63
$96.17
52-Wochen-Spanne:
$33.19
$96.28
Merus N V Stock (MRUS) Company Profile
Firmenname
Merus N V
Sektor
Branche
Telefon
31 030 253 8800
Adresse
YALELAAN 62, 3584 CM UTRECHT
Vergleichen Sie MRUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
95.76 | 7.28B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-08-25 | Eingeleitet | Alliance Global Partners | Buy |
| 2025-02-13 | Eingeleitet | Piper Sandler | Overweight |
| 2025-02-07 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-21 | Eingeleitet | Goldman | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-03-28 | Eingeleitet | Truist | Buy |
| 2024-03-04 | Bestätigt | Needham | Buy |
| 2023-11-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-08-21 | Eingeleitet | TD Cowen | Outperform |
| 2022-08-02 | Eingeleitet | Stifel | Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Needham | Buy |
| 2021-11-17 | Fortgesetzt | Guggenheim | Buy |
| 2021-06-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-08 | Eingeleitet | William Blair | Outperform |
| 2021-03-16 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-27 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | Fortgesetzt | Guggenheim | Buy |
| 2019-06-28 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Fortgesetzt | Guggenheim | Buy |
| 2019-04-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | Eingeleitet | Berenberg | Buy |
| 2018-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-03-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-12-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2016-11-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-06-13 | Eingeleitet | Citigroup | Buy |
| 2016-06-13 | Eingeleitet | Guggenheim | Buy |
| 2016-06-13 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Merus N V Aktie (MRUS) Neueste Nachrichten
Halper Sadeh LLC Encourages EXAS, NVRI, MRUS Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire
Halper Sadeh LLC Encourages EXAS, NVRI, MRUS Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-MRUS, ACLS, VECO, and CLCO - The Malaysian Reserve
Why Merus N.V. (2GH) stock attracts wealthy investorsWeekly Loss Report & High Conviction Trade Alerts - newser.com
Is Merus N.V. (2GH) stock supported by free cash flowQuarterly Trade Report & Weekly Momentum Picks - newser.com
Will Merus N.V. stock split again soonExit Point & Stepwise Trade Signal Guides - newser.com
Why Merus N.V. (2GH) stock could be next leader2025 Earnings Impact & Reliable Trade Execution Plans - newser.com
Will Merus N.V. stock deliver strong dividend growth2025 Trade Ideas & Fast Entry Momentum Trade Alerts - newser.com
How Merus N.V. (2GH) stock reacts to stronger dollarBull Run & Low Drawdown Investment Ideas - newser.com
Will Merus N.V. stock reach Wall Street targetsWeekly Investment Recap & Weekly Return Optimization Plans - newser.com
Can Merus N.V. stock maintain growth trajectoryJuly 2025 Snapshot & Weekly Watchlist for Hot Stocks - newser.com
Is Merus N.V. stock a buy for dividend growthPortfolio Performance Report & Stock Market Timing Techniques - newser.com
Can Merus N.V. (2GH) stock test all time highsBear Alert & Daily Price Action Insights - newser.com
What market sentiment indicators show for Merus N.V. (2GH) stock2025 Investor Takeaways & AI Enhanced Trading Signals - newser.com
Will Merus N.V. stock split attract more investors2025 Major Catalysts & Breakout Confirmation Trade Signals - newser.com
Is Merus N.V. stock bottoming outMarket Performance Recap & Stock Portfolio Risk Management - newser.com
Genmab prices $2.5 billion in notes to fund Merus acquisition By Investing.com - Investing.com Australia
Will Merus N.V. stock deliver better than expected guidancePortfolio Return Summary & Low Risk Growth Stock Ideas - newser.com
Key metrics from Merus N.V.’s quarterly dataTrade Signal Summary & Capital Efficient Trading Techniques - newser.com
Can Merus N.V. (2GH) stock sustain revenue momentum2025 Market Overview & Daily Price Action Insights - newser.com
Will Merus N.V. (2GH) stock keep high P E multiplesWeekly Trading Summary & Free Weekly Watchlist of Top Performers - newser.com
How Halozyme’s ENHANZE Licensing Deal With Merus May Strengthen Royalty Pipeline for HALO Investors - simplywall.st
Finanzdaten der Merus N V-Aktie (MRUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):